Arbutus Biopharma Corp Accrued Investment Income Receivable
Arbutus Biopharma Corp (ABUS) had Accrued Investment Income Receivable of $400.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2026-08-12
- 2026-06-30: Accrued Investment Income Receivable $400.00K.
- 2026-03-31: Accrued Investment Income Receivable $300.00K.
- 2025-12-31: Accrued Investment Income Receivable $300.00K.
- 2025-09-30: Accrued Investment Income Receivable $300.00K.
| Period end | Accrued Investment Income Receivable |
|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $300.00K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $100.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $200.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $300.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $300.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $300.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $600.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $600.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $600.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $600.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $600.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $600.00K 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |